{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:42:38Z","timestamp":1787010158186,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Jiangsu Women and Children Health Hospital The Youth Talent Launch Fund","award":["FYRC202007"],"award-info":[{"award-number":["FYRC202007"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Malignant melanoma is a highly malignant tumor originating from the melanocytes of the neural crest, which is prone to metastasis and has a poor prognosis. Previous research demonstrated that melanoma inhibitory activity (MIA) and lactate dehydrogenase (LDH) could serve as serum markers in malignant melanoma and indicate prognosis in the Caucasian race. Researchers suspected that both MIA and LDH could prompt the prognosis of malignant melanoma in the Chinese population. This study aimed to investigate the value of MIA and LDH in the prognosis of acral malignant melanoma.<\/jats:p>\n                    <jats:p>From January 1, 2014, to December 31, 2017, in Jiangsu Province, 44 acral malignant melanoma patients with complete data were chosen from the clinic. The LDH levels were extracted from their clinical data, and MIA levels were measured by enzyme-linked immunosorbent assay method. 8 paired advancing samples before and after metastasis were examined. 22 health donors were matched to the patient group. Receiver operating characteristic (ROC) curves of MIA and LDH were drawn to determine acral malignant melanoma tumorigenesis and metastasis and finally got the cut-off value. Cumulative survival was illustrated with the Kaplan-Meier plot, and factors were compared using the Log-rank test.<\/jats:p>\n                    <jats:p>\n                      Compared with age-matched healthy donors, MIA was significantly high in patients (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a&lt;\u200a.001). Moreover, serum MIA was significantly higher in III-IV stage patients than I-II stage patients (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a&lt;\u200a.001). However, there was no such association between LDH and melanoma stage and risk. Further study indicated that the MIA cut-off &gt; 914.7pg\/mL predicted disease progression with 86.4% specificity and 95.5% sensitivity. In the Kaplan-Meier analysis, MIA levels were independent risk factors for long-term mortality of acral malignant melanoma patients.\n                    <\/jats:p>\n                    <jats:p>It concluded that the quantification of MIA in the serum should be performed as a general standard of care in patients at risk of developing metastatic melanoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000024840","type":"journal-article","created":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T20:01:49Z","timestamp":1614888109000},"page":"e24840","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["The value of melanoma inhibitory activity and LDH with melanoma patients in a Chinese population"],"prefix":"10.1097","volume":"100","author":[{"given":"Chujun","family":"Li","sequence":"first","affiliation":[{"name":"Department of Plastic and Burns Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Plastic and Burns Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjing","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9040-4284","authenticated-orcid":false,"given":"Gang","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Plastic and Burns Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,2,26]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3322\/caac.21409","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"157","DOI":"10.28991\/esj-2019-01178","article-title":"Developing an integrated genomic profile for cancer patients with the use of NGS data","volume":"3","author":"Kosvyra","year":"2019","journal-title":"Emerg Sci J"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.28991\/SciMedJ-2020-0201-1","article-title":"Raman-Enhanced Spectroscopy (RESpect) Probe for Childhood Non-Hodgkin Lymphoma","volume":"2","author":"Agsalda-Garcia","year":"2020","journal-title":"SciMedicine Journal"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"100","DOI":"10.28991\/SciMedJ-2020-0202-7","article-title":"Differential diagnosis of malignant melanoma and benign cutaneous lesions by ultrasound analysis","volume":"2","author":"Hambardzumyan","year":"2020","journal-title":"SciMedicine Journal"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1126\/science.aao6963","article-title":"New insights into melanoma development","volume":"357","author":"Shay","year":"2017","journal-title":"Science (New York, NY)"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"25","DOI":"10.28991\/SciMedJ-2019-0101-4","article-title":"Effects of salvia officinalis extract on the breast cancer cell line","volume":"1","author":"Zare","year":"2019","journal-title":"SciMedicine Journal"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/exd.12281","article-title":"Melanoma inhibitory activity in melanoma diagnostics and therapy - a small protein is looming large","volume":"23","author":"Riechers","year":"2014","journal-title":"Exp Dermatol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"e37941","DOI":"10.1371\/journal.pone.0037941","article-title":"Targeting melanoma metastasis and immunosuppression with a new mode of melanoma inhibitory activity (MIA) protein inhibition","volume":"7","author":"Schmidt","year":"2012","journal-title":"PloS One"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1758835920970050","DOI":"10.1177\/1758835920970050","article-title":"Lactate dehydrogenase kinetics predict chemotherapy response in recurrent metastatic nasopharyngeal carcinoma","volume":"12","author":"Huang","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1158\/1078-0432.CCR-10-2402","article-title":"Plasma markers for identifying patients with metastatic melanoma","volume":"17","author":"Kluger","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/CMR.0b013e328347105e","article-title":"Receiver operating characteristic analysis: calculation for the marker \u2019melanoma inhibitory activity\u2019 in metastatic uveal melanoma patients","volume":"21","author":"Klingenstein","year":"2011","journal-title":"Melanoma Res"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s00417-005-1171-4","article-title":"Melanoma inhibitory activity\u201d (MIA): a promising serological tumour marker in metastatic uveal melanoma","volume":"243","author":"Reiniger","year":"2005","journal-title":"Graefe's Arch Clin Exp Ophthalmol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.ejca.2006.11.022","article-title":"Clinical value of combined determination of plasma L-DOPA\/tyrosine ratio, S100B, MIA and LDH in melanoma","volume":"43","author":"Garnier","year":"2007","journal-title":"Eur J Cancer"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/ijc.27991","article-title":"Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein. International journal of cancer","volume":"133","author":"Henry","year":"2013","journal-title":"Int J Cancer"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1470-2045(18)30078-0","article-title":"Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis","volume":"19","author":"McQuade","year":"2018","journal-title":"Lancet Oncol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.soc.2014.12.009","article-title":"Role for radiation therapy in melanoma","volume":"24","author":"Shi","year":"2015","journal-title":"Surg Oncol Clin N Am"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.1002\/jcp.26395","article-title":"MicroRNAs in cutaneous melanoma: role as diagnostic and prognostic biomarkers","volume":"233","author":"Ross","year":"2018","journal-title":"J Cell Physiol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/eye.2015.51","article-title":"Prognosis of uveal melanoma based on race in 8100 patients: The 2015 Doyne Lecture","volume":"29","author":"Shields","year":"2015","journal-title":"Eye (London, England)"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"e3315","DOI":"10.1097\/MD.0000000000003315","article-title":"Association between race\/ethnicity and survival of melanoma patients in the United States over 3 Decades: a secondary analysis of SEER Data","volume":"95","author":"Ward-Peterson","year":"2016","journal-title":"Medicine"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12967-018-1452-4","article-title":"Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors","volume":"16","author":"Gowen","year":"2018","journal-title":"J Transl Med"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/CMR.0000000000000375","article-title":"Characteristics of melanoma in Japan: a nationwide registry analysis 2011-2013","volume":"27","author":"Tomizuka","year":"2017","journal-title":"Melanoma Res"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"6348","DOI":"10.1158\/1078-0432.CCR-12-1397","article-title":"Serum lactate dehydrogenase is prognostic for survival in patients with bone metastases from breast cancer: a retrospective analysis in bisphosphonate-treated patients","volume":"18","author":"Brown","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R23-20250504","first-page":"2459","article-title":"Change in serum lactate dehydrogenase is associated with outcome of patients with advanced-stage NSCLC treated with Erlotinib","volume":"36","author":"Fiala","year":"2016","journal-title":"Anticancer Res"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"9800","DOI":"10.1038\/srep09800","article-title":"Prognostic value of pretreatment serum lactate dehydrogenase level in patients with solid tumors: a systematic review and meta-analysis","volume":"5","author":"Zhang","year":"2015","journal-title":"Sci Rep"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41416-018-0167-x","article-title":"S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies","volume":"119","author":"Wagner","year":"2018","journal-title":"Br J Cancer"},{"key":"R26-20250504","first-page":"449","article-title":"Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma","volume":"63","author":"Kelderman","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"R27-20250504","first-page":"5358","article-title":"Autocrine tumor cell growth-inhibiting activities from human malignant melanoma","volume":"49","author":"Bogdahn","year":"1989","journal-title":"Cancer Res"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/CMR.0b013e32831bc78c","article-title":"Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma","volume":"19","author":"Hofmann","year":"2009","journal-title":"Melanoma Res"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1590\/abd1806-4841.20153248","article-title":"Melanoma inhibitory activity in Brazilian patients with cutaneous melanoma","volume":"90","author":"Odashiro","year":"2015","journal-title":"Anais brasileiros de dermatologia"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/01.COC.0000054895.39558.DB","article-title":"Clinical value of protein S100 and melanoma-inhibitory activity (MIA) in malignant melanoma","volume":"27","author":"Tas","year":"2004","journal-title":"Am J Clin Oncol"},{"key":"R31-20250504","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11060750","article-title":"Lactate dehydrogenases as metabolic links between tumor and stroma in the tumor microenvironment","volume":"11","author":"Mishra","year":"2019","journal-title":"Cancers"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000024840","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:09:25Z","timestamp":1746324565000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000024840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,26]]},"references-count":31,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000024840","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,26]]},"assertion":[{"value":"2020-03-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}